Maegim한국어

나이벡

138610KOSDAQSector: Pharma & Biotech
₩13,740▼ 4.65%Market cap ₩156.2BAs of Jul 21, 2026 close · updated once daily
A
Grade A69.6 ptsTop 12% of 2,523 stocks
Financial strength
77.5
Growth momentum
88.1
Price attractiveness
47.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

77.5
How much debt does it carry relative to equity?
Debt-to-equity ratio
37.5%
✓ Above median · Top 33.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
316.2%
✓ Above median · Top 33.1% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
15.4%
✓ Above median · Top 11.3% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
10.1%
✓ Above median · Top 11.6% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

88.1
How much did revenue grow in a year?
Revenue growth (YoY)
33.3%
✓ Above median · Top 16.7% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.7%
✓ Above median · Top 20.1% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
202.0%
✓ Above median · Top 8.3% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
678.4%
✓ Above median · Top 2.4% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

47.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
33.6x
✓ Above median · Top 33.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
3.41x
✗ Below median · Top 71.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15